v3.26.1
Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)
6 Months Ended
Mar. 31, 2026
Mar. 31, 2025
REVENUE    
Total revenue $ 8,919,382 $ 9,881,505
COST OF REVENUE AND RELATED TAX    
Cost of revenue (6,458,544) (7,348,488)
Business and sales related tax (63,383) (130,495)
Total cost of revenue and related tax (6,521,927) (7,478,983)
GROSS PROFIT 2,397,455 2,402,522
OPERATING EXPENSES    
Selling expenses (712,016) (747,258)
General and administrative expenses (1,448,166) (1,448,590)
Research and development expenses (881,726) (660,886)
Total operating expenses (3,041,908) (2,856,734)
LOSS FROM OPERATIONS (644,453) (454,212)
OTHER INCOME (EXPENSE)    
Interest income, net 38,398 301,535
Foreign exchange (losses) gains, net (242,982) 58,857
Other income, net 543,991 122,384
Total other income, net 339,407 482,776
(LOSS) INCOME BEFORE INCOME TAXES (305,046) 28,564
INCOME TAX BENEFITS (EXPENSES) 96,042 (19,566)
NET (LOSS) INCOME (209,004) 8,998
Less: net (loss) income attributable to non-controlling interest (101,269) 98,006
NET LOSS ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD. (107,735) (89,008)
COMPREHENSIVE INCOME (LOSS)    
Net (loss) income (209,004) 8,998
Foreign currency translation gain (loss) 785,341 (805,137)
Comprehensive income (loss) 576,337 (796,139)
Less: comprehensive (loss) income attributable to non-controlling interest (104,835) 106,495
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO JIN MEDICAL INTERNATIONAL LTD. $ 681,172 $ (902,634)
Loss per ordinary share - basic (in Dollars per share) $ (0.01) $ (0.01)
Loss per ordinary share - diluted (in Dollars per share) $ (0.01) $ (0.01)
Weighted average shares - basic (in Shares) [1] 7,827,357 7,827,355
Weighted average shares - diluted (in Shares) [1] 7,827,357 7,827,355
Third party    
REVENUE    
Revenue $ 8,766,226 $ 9,678,459
Related Party    
REVENUE    
Revenue $ 153,156 $ 203,046
[1] Retrospectively adjusted to reflect the 1-for-20 reverse share split effective on March 16, 2026.